BDA
16.3.2022 20:53:09 CET | Business Wire | Press release
The sold-out Bermuda Business Development Agency’s (BDA) Bermuda Risk Summit was declared an immense success, with over 80 overseas delegates in attendance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220316005995/en/
The immediate economic impact of the event, which had a total of 350 delegates, including lodging, transportation, food and beverage, retail and recreation was estimated at over one million dollars, and supported around 200 jobs. Based on market feedback, dozens of additional visitors flew to Bermuda for business meetings around the event, bringing additional economic impacts to the island.
The Hon. Jason Hayward, JP, MP, Minister of Economy and Labour, who attended the event, said, “Congratulations to the BDA for organising such a successful inaugural event which had a positive impact on Bermuda’s economy and community. Bermuda remains the world’s risk capital, and for decades, Bermuda based insurers have been leaders in the global reinsurance industry. It was a pleasure to meet and hear first-hand updates from some of the world’s foremost risk and regulatory experts. The Government along with the Bermuda Monetary Authority (BMA) plays a critical role in the success of Bermuda’s Insurance Industry and remains a partner, committed to supporting the growth of the industry.”
David Hart, BDA CEO, said, “We received fantastic feedback for taking a leadership role in organising the first in-person risk event since 2019. A running theme across the event was how great it was to get off zoom and see each other again in person after such a long absence. Our hope was always that this event would provide an opportunity for Bermuda’s risk industry to start charting a way forward together and meet prior to mid-year renewal season. We look forward to building on this success by making our second annual event on March 6-8, 2023, even bigger and better next year.”
The Risk Summit was kicked off by a ‘sea-side’ chat between Bermuda’s Premier, The Hon. David Burt, JP, MP, and Mr. Hart. In his remarks, Premier Burt said, “Thank you to all those who are visiting but thank you also to our risk industry who throughout this pandemic has been a bedrock of support inside of the community...The objective of this government as we move beyond the pandemic is to make sure that Bermuda maintains its leadership across the board and remains the most competitive place to deploy capital.”
The seaside chat was followed by a panel made up of global CEOs, including Albert Benchimol, President & CEO, Axis; Stephen Catlin, Chairman & CEO, Convex; Marc Grandisson, CEO, Arch Capital Group; Chris Schaper, CEO, AIG Re; and Megan Thomas, CEO, Hamilton Re. In his remarks, CEO panel moderator John Huff, CEO, of the Association of Bermuda Insurers and Reinsurers (ABIR) welcomed the three ABIR-sponsored Bermuda College students in the audience. Also in the audience was a contingent of risk and insurance students from Eastern Kentucky University who flew down especially for the event and to learn about Bermuda’s globally important risk industry.
Day two started off with breakfast keynote on terrorism risk from Julian Enoizi, CEO Pool Re, and was followed by panels featuring rating agencies, brokers, life, and a Florida Legislative Update. Day two was rounded off by an incredible keynote lunch featuring Aon President, Eric Andersen.
Our final day began with a keynote on Florida risk by Joseph Petrelli, President, Demotech, with panels on captives, cyber, InsurTech, and Insurance Linked Securities (ILS) following. Day 3 was closed out by remarks about an upcoming Bermuda ESG benchmarking survey by Miqdaad Versi, Head of ESG, Oxbow Partners, UK.
The BDA thanks our diamond sponsors, ABIR, Aon and EY, our gold sponsor Appleby, and our silver sponsors Ariel Re, Kirkland & Ellis, KPMG, and SiriusPoint. We were also fortunate to have Bermuda Brokers, Florida Insurance Council, Kettle, Meenan P.A., and Goslings as additional event sponsors. Our media partner was The Insurer. The Bermuda Risk Summit was a SafeKey event.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, relocate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220316005995/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom